Neurocrine Biosciences reported 22.1 in PE Price to Earnings for its fiscal quarter ending in June of 2026.





Pe Change Date
AbbVie 23.96 0.93 Jun/2026
Acadia Pharmaceuticals 11.33 1.25 Jun/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
ALKERMES 135.81 96.48 Jun/2026
Alnylam Pharmaceuticals 75.64 4.4 Jun/2026
Amgen 18.07 1.77 Jun/2026
Biogen 23.23 9.53 Jun/2026
BioMarin Pharmaceutical 21.07 5.79 Jun/2026
Exelixis 18.02 4.11 Jun/2026
Gilead Sciences 13.51 4.2 Jun/2026
Halozyme Therapeutics 12.51 1.15 Jun/2026
Incyte 14.45 0.9 Jun/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Neurocrine Biosciences 22.1 5.99 Jun/2026
Pfizer 11.48 2.16 Jun/2026
Prothena 22.11 11.37 Mar/2022
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Repligen 105.09 4.39 Jun/2026
Rigel Pharmaceuticals 8.61 8.4 Mar/2025
Sarepta Therapeutics 27.27 0 Mar/2026
Teva Pharmaceutical Industries 24.6 14.53 Jun/2026
Vertex Pharmaceuticals 28.05 2.22 Jun/2026